ReviewAnnals of translational medicine2017
Neopterin as a biomarker of immune response in cancer patients.
Review in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Genetic co-regulation of neopterin and Parkinson's disease.NPJ Parkinson's disease · 2026Article
- The Role of Neopterin and Interleukin-6 Detection in Saliva and Plasma in Oral and Oropharyngeal Cancer Patients: A Prospective Study.Clinical and experimental dental research · 2025Article
- Urinary kynurenine,tryptophan, and neopterin concentrations during physiological pregnancy.Scientific reports · 2025Article
- Low serum neopterin early indicates durable benefits of atezolizumab and pembrolizumab therapy in advanced lung cancer.Scientific reports · 2025Article
- Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients.Frontiers in microbiology · 2025Article
- Stratification of Sepsis Patients on Admission into the Intensive Care Unit According to Differential Plasma Metabolic Phenotypes.Journal of proteome research · 2024Article
- Volabolomic Fingerprinting for Post-Mortem Interval Estimation: A Novel Physiological Approach.Biomolecules · 2024Article
- Enhanced expression of neopterin in valve tissue of bicuspid aortic stenosis.Journal of thoracic disease · 2024Article
- Elevated neopterin and decreased IL-4, BDNF levels and depression in lymphoma patients receiving R-CHOP chemotherapy.Frontiers in neurology · 2024Article
- Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever.Irish journal of medical science · 2023Article
- Oxidative Stress Response Kinetics after 60 Minutes at Different Levels (10% or 15%) of Normobaric Hypoxia Exposure.International journal of molecular sciences · 2023Article
- Neopterin, the Cell-Mediated Immune Response Biomarker, in Inflammatory Periodontal Diseases: A Narrative Review of a More than Fifty Years Old Biomarker.Biomedicines · 2023Review
- Article
- Insights into Molecular Structure of Pterins Suitable for Biomedical Applications.International journal of molecular sciences · 2022Review
- Morphological Assessment and Biomarkers of Low-Grade, Chronic Intestinal Inflammation in Production Animals.Animals : an open access journal from MDPI · 2022Review
- Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma.Experimental and therapeutic medicine · 2022Article
- Article
- Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.Drug design, development and therapy · 2022Review
- The potential role of neopterin in Covid-19: a new perspective.Molecular and cellular biochemistry · 2021Review
- Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the advent of immunotherapy the topic of biomarkers of immune response is of high interest. Along with the expression of programmed death ligand 1 (PD-L1) or tumor infiltrating lymphocytes (TIL), biomarkers of macrophage activation could be of interest. Neopterin is a biomarker of immune activation increased in different disorders associated with immune activation, including cancer. Neopterin synthesis is induced by interferon-γ that also induces indoleamine 2,3-dioxygenase (IDO), an enzyme catalyzing catabolism of tryptophan to kynurenine. Increased urinary or serum concentrations of neopterin have been associated with poor prognosis across a spectrum of malignant disorders of different primary location. Neopterin concentration in peripheral blood as well as in the tumor microenvironment correlates with phenotypic and functional changes of lymphocytes, indicating immune dysfunction. Increased neopterin concentrations are also accompanied by increased rate of conversion of tryptophan to kynurenine. Increasing neopterin concentrations also accompany side effects of anticancer treatment and could predict subsequent complications. Although almost four decades have elapsed since the discovery of increased neopterin concentrations in cancer patients, the full potential of neopterin as a biomarker in this setting has not been so far realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.